MeNow

Company Overview

Snapshot

Founded in July 2022 by Hilla Ben-Hamo and Coralie Ebert, MeNow operates with 11–50 employees. The company is currently in a Pre-Funding stage, focusing on the development of novel natural bioactive compounds. A key milestone for MeNow was its collaboration with Green Mountain Biotech in January 2023 to develop AI-based skincare products.

Business overview

MeNow is an AI-driven discovery company specializing in identifying and validating natural bioactive compounds for applications in food, cosmetics, and health. The company leverages advanced probabilistic AI, systems biology, and molecular science to pinpoint new bioactives with strong efficacy, safety, and scalability. MeNow's technology has led to breakthroughs in longevity-relevant biology, generating proprietary intellectual property around pathways such as SIRT1 activation, heparanase modulation, and GLP-1–associated mechanisms, with broad applications across metabolic health, inflammation, tissue function, and healthspan support. It operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Cosmetic Materials industries.

Strategic signal

In January 2023, MeNow announced a strategic collaboration with Green Mountain Biotech to develop AI-based skincare products derived from Traditional Chinese Medicine. This partnership signals MeNow's ability to translate its AI-driven discovery platform into commercial applications within the cosmetics industry, validating its technology for identifying effective and safe natural ingredients. For investors, this demonstrates a clear path to market for its bioactives and an expansion of its intellectual property into a high-growth consumer segment.

Company Intelligence Q&A

What is MeNow's core focus?

MeNow is an AI-driven discovery company focused on developing novel natural bioactive compounds for the food, cosmetics, and health industries.

When was MeNow founded and by whom?

MeNow was founded in July 2022 by co-founders Hilla Ben-Hamo and Coralie Ebert.

How does MeNow identify bioactive compounds?

MeNow integrates advanced probabilistic AI, systems biology, and molecular science to identify and validate new bioactives with strong efficacy, safety, and scalability profiles.

What significant partnership did MeNow announce?

In January 2023, MeNow announced a collaboration with Green Mountain Biotech for the AI-based development of skincare products based on Traditional Chinese Medicine.

What are the key biological pathways MeNow's technology addresses?

MeNow has generated proprietary intellectual property around key pathways such as SIRT1 activation, heparanase modulation, and GLP-1–associated mechanisms, with applications across metabolic health, inflammation, tissue function, and healthspan support.